Transgene, AstraZeneca enter into a collaboration for Invir.IO based armed oncolytic immunotherapies

This article was originally published here

Innovative oncolytic viruses resulting from this collaboration will use Transgene’s proprietary next generation viral platform Invir.IO. Under the terms of the agreement Transgene will contribute its oncolytic virus

The post Transgene, AstraZeneca enter into a collaboration for Invir.IO based armed oncolytic immunotherapies appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply